Number of the records: 1
Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines
- Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines / J. Knillová ... [et al.] . Neoplasma : journal of experimental and clinical oncology. - ISSN 0028-2685 . - Vol. 51, no. 5 (2004), p. 358-367 : Obr., tab.
- C 720
article
Number of the records: 1